Samuel Hochstrasser’s practice focuses on domestic and cross-border M&A, capital markets and private equity transactions. His expertise includes corporate, commercial and contract law. He has particular knowledge of the life sciences sector, advising on regulatory and legal in life science matters.


Recent matters in which Samuel acted as counsel include:

  • Landis+Gyr Group and its shareholders Toshiba and INCJ in the dual track exit process resulting in the CHF 2.3 billion IPO of Landis+Gyr Group on SIX, the largest Swiss IPO of the past 10 years and second largest IPO in Europe 2017

  • Actelion in connection with the public tender offer by Johnson & Johnson to the shareholders of Actelion and in connection with the demerger of Idorsia from Actelion

  • BioTelemetry, Inc. in connection with its competing public tender offer to the shareholders of LifeWatch AG

  • Swiss Bar Association
  • Zurich Bar Association
  • HSG Alumni

News & Insights